{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:28:38Z","timestamp":1780590518976,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1U01 DK089533"],"award-info":[{"award-number":["1U01 DK089533"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.vaccine.2014.02.070","type":"journal-article","created":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T06:45:21Z","timestamp":1394865921000},"page":"2300-2307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["An oral vaccine for type 1 diabetes based on live attenuated Salmonella"],"prefix":"10.1016","volume":"32","author":[{"given":"Mohamed I.","family":"Husseiny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Todorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Kandeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.070_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0010","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1084\/jem.20070590","article-title":"A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism","volume":"204","author":"Coombes","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0015","first-page":"293","article-title":"Autoantigen based vaccines for type 1 diabetes","volume":"11","author":"Nicholas","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0020","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/db10-0630","article-title":"Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential","volume":"59","author":"Peakman","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/dia.2009.0116","article-title":"Autoantigens plus interleukin-10 suppress diabetes autoimmunity","volume":"12","author":"Denes","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1385\/MB:34:3:317","article-title":"Suppression of hyperglycemia in NOD mice after inoculation with recombinant vaccinia viruses","volume":"34","author":"Denes","year":"2006","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3410\/B2-75","article-title":"Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets","volume":"2","author":"Moser","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.coi.2007.11.005","article-title":"Insulin as an autoantigen in NOD\/human diabetes","volume":"20","author":"Zhang","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/dmrr.941","article-title":"Therapy with GAD in diabetes","volume":"25","author":"Ludvigsson","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0050","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.4049\/jimmunol.176.5.2781","article-title":"Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects","volume":"176","author":"Yang","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ni.1844","article-title":"Chromogranin A is an autoantigen in type 1 diabetes","volume":"11","author":"Stadinski","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0060","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2337\/db11-0288","article-title":"Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells","volume":"60","author":"Delong","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/cei.12085","article-title":"Progress in immune-based therapies for type 1 diabetes","volume":"172","author":"von Herrath","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0070","doi-asserted-by":"crossref","first-page":"a007773","DOI":"10.1101\/cshperspect.a007773","article-title":"Antigen-specific therapeutic approaches in type 1 diabetes","volume":"2","author":"Clemente-Casares","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clim.2010.10.004","article-title":"GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients","volume":"138","author":"Hjorth","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(11)60895-7","article-title":"Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial","volume":"378","author":"Wherrett","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0085","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/193229680900300213","article-title":"Linkoping diabetes immune intervention study G. The role of immunomodulation therapy in autoimmune diabetes","volume":"3","author":"Ludvigsson","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0090","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0095","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijmm.2007.08.006","article-title":"Rational design of Salmonella recombinant vaccines","volume":"298","author":"Cheminay","year":"2008","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0105","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/ijc.24957","article-title":"Novel cancer vaccine based on genes of Salmonella pathogenicity island 2","volume":"126","author":"Xiong","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0110","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2009.03.053","article-title":"Evaluation of Salmonella live vaccines with chromosomal expression cassettes for translocated fusion proteins","volume":"27","author":"Husseiny","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.vaccine.2005.11.020","article-title":"Recombinant vaccines based on translocated effector proteins of Salmonella pathogenicity island 2","volume":"25","author":"Husseiny","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0120","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.vaccine.2004.11.035","article-title":"Evaluation of an intracellular-activated promoter for the generation of live Salmonella recombinant vaccines","volume":"23","author":"Husseiny","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0125","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1462-5822.2006.00706.x","article-title":"Manipulating cellular transport and immune responses: dynamic interactions between intracellular Salmonella enterica and its host cells","volume":"8","author":"Abrahams","year":"2006","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nri2335","article-title":"Dendritic cells in intestinal immune regulation","volume":"8","author":"Coombes","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0135","doi-asserted-by":"crossref","first-page":"17729","DOI":"10.1073\/pnas.0509006102","article-title":"Endocrine self and gut non-self intersect in the pancreatic lymph nodes","volume":"102","author":"Turley","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0140","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI28045","article-title":"In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines","volume":"116","author":"Nishikawa","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0145","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/JVI.77.4.2400-2409.2003","article-title":"Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system","volume":"77","author":"Evans","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0150","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-10-4676","article-title":"Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors","volume":"71","author":"Manuel","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0155","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1615\/CritRevImmunol.v30.i3.30","article-title":"New technologies in using recombinant attenuated Salmonella vaccine vectors","volume":"30","author":"Curtiss","year":"2010","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0160","doi-asserted-by":"crossref","first-page":"E1323","DOI":"10.1152\/ajpendo.90617.2008","article-title":"Evaluating the glucose tolerance test in mice","volume":"295","author":"Andrikopoulos","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0165","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/TP.0b013e3181f1db5d","article-title":"Quantitative assessment of beta-cell apoptosis and cell composition of isolated, undisrupted human islets by laser scanning cytometry","volume":"90","author":"Todorov","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0170","first-page":"1231","article-title":"Clinical use of the glucose disappearance rate","volume":"88","author":"Saucier","year":"1963","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1172\/JCI102755","article-title":"Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus","volume":"32","author":"Amatuzio","year":"1953","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0180","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1084\/jem.20080414","article-title":"Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans","volume":"205","author":"Jaensson","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0185","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1084\/jem.20070602","article-title":"Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid","volume":"204","author":"Sun","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0190","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/IAI.73.3.1598-1605.2005","article-title":"Rapid method for the construction of Salmonella enterica Serovar typhimurium vaccine carrier strains","volume":"73","author":"Husseiny","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0195","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1172\/JCI60530","article-title":"Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice","volume":"122","author":"Takiishi","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0200","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1016\/S0264-410X(02)00301-8","article-title":"Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence","volume":"20","author":"Grangette","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000100515","article-title":"Vivotif\u2014a \u2018magic shield\u2019 for protection against typhoid fever and delivery of heterologous antigens","volume":"53","author":"Gentschev","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/infdis\/166.1.210","article-title":"Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies","volume":"166","author":"Forrest","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0215","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0264-410X(91)90130-X","article-title":"Active immunity is seen as a reduction in the cell response to oral live vaccine","volume":"9","author":"Kantele","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0264-410X(96)00158-2","article-title":"Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain","volume":"15","author":"Attridge","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors--friend or foe","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0230","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/IAI.71.1.287-297.2003","article-title":"Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines","volume":"71","author":"Vindurampulle","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0235","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1128\/IAI.59.10.3841-3845.1991","article-title":"Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers","volume":"59","author":"Bao","year":"1991","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0240","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.vaccine.2008.01.044","article-title":"Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction","volume":"26","author":"Sevil Dom\u00e8nech","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0245","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/db11-1213","article-title":"Central role for interleukin-2 in type 1 diabetes","volume":"61","author":"Hulme","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0255","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.4049\/jimmunol.171.5.2270","article-title":"Systemic overexpression of IL-10 induces CD4+ CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion","volume":"171","author":"Goudy","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/clin.1994.1068","article-title":"Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse","volume":"71","author":"Pennline","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0265","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.4049\/jimmunol.165.12.7330","article-title":"A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes","volume":"165","author":"Balasa","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.02.070_bib0270","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.4049\/jimmunol.165.5.2841","article-title":"Islet-specific expression of IL-10 promotes diabetes in nonobese diabetic mice independent of Fas, perforin, TNF receptor-1, and TNF receptor-2 molecules","volume":"165","author":"Balasa","year":"2000","journal-title":"J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T01:08:53Z","timestamp":1716599333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":54,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0264410X14002977"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.070","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An oral vaccine for type 1 diabetes based on live attenuated Salmonella","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}